<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Suggested antimycobacterial regimens for NTM pulmonary infections in children&lt;sup&gt;[1-3]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Suggested antimycobacterial regimens for NTM pulmonary infections in children<sup>[1-3]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Suggested antimycobacterial regimens for NTM pulmonary infections in children<sup>[1-3]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup> <colgroup span="2" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">Mycobacteria species and patient characteristics</td> <td class="subtitle1">Suggested regimen</td> <td class="subtitle1">Comments</td> </tr> <tr> <td class="subtitle2_left" colspan="3"><em>Mycobacterium tuberculosis</em> not yet excluded</td> </tr> <tr> <td class="indent1"> </td> <td> <ul> <li>Isoniazid, <strong>plus</strong></li> <li>Rifampin (rifampicin), <strong>plus</strong></li> <li>Ethambutol, <strong>plus</strong></li> <li>Azithromycin (preferred*) or clarithromycin, <strong>plus</strong></li> <li>Pyrazinamide<sup>¶</sup></li> </ul> </td> <td> <ul> <li>Provides empiric coverage for <em>M. tuberculosis</em> and two NTM species commonly isolated from children with NTM pulmonary disease (MAC and <em>Mycobacterium kansasii</em>)</li> <li>Modify regimen when NTM species is identified and speciation <em>M. tuberculosis</em> is confirmed or excluded</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="3">MAC infection</td> </tr> <tr> <td class="indent1">HIV-negative, with nodular or noncavitating disease</td> <td> <ul> <li>A rifamycin (rifampin [rifampicin] or rifabutin), <strong>plus</strong></li> <li>Ethambutol, <strong>plus</strong></li> <li>Azithromycin (preferred*) or clarithromycin</li> </ul> </td> <td> <ul> <li>Administer regimen 3 times per week</li> <li>Continue until sputum cultures negative for ≥1 year</li> </ul> </td> </tr> <tr> <td class="indent1">HIV-negative, with fibrocavitary disease or extensive bronchiectasis</td> <td> <ul> <li>A rifamycin (rifampin [rifampicin] or rifabutin), <strong>plus</strong></li> <li>Ethambutol, <strong>plus</strong></li> <li>Azithromycin (preferred*) or clarithromycin, <strong>plus</strong></li> <li>An aminoglycoside (amikacin or streptomycin)</li> </ul> </td> <td> <ul> <li>Administer rifamycin, ethambutol, and macrolide daily</li> <li>Aminoglycoside: <ul> <li>For children: Administer daily</li> <li>For adolescents: Amikacin may be administered 3 times per week</li> </ul> </li> <li>Discontinue aminoglycoside after 8 weeks</li> <li>Continue other agents until sputum cultures negative for ≥1 year</li> </ul> </td> </tr> <tr> <td class="indent1">HIV-positive</td> <td> <ul> <li>Treat as for children with disseminated NTM infection</li> </ul> </td> <td> <ul> <li>Refer to UpToDate content on disseminated NTM infection</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="3"><em>Mycobacterium abscessus</em> infection</td> </tr> <tr> <td class="indent1"> </td> <td> <ul> <li>Azithromycin (preferred*) or clarithromycin, <strong>plus</strong></li> <li>Amikacin, <strong>plus</strong></li> <li>Cefoxitin or a carbapenem (eg, imipenem, meropenem)</li> <li>For <em>M. abscessus</em> subspecies <em>abscessus</em> or <em>M. abscessus</em> subspecies <em>bolletii</em>, add another drug (eg, linezolid, tigecycline)<sup>Δ</sup></li> </ul> </td> <td> <ul> <li>Select drugs based on susceptibility testing</li> <li>Use at least 3 active drugs initially; may narrow to 2 drugs after 4 to 8 weeks</li> <li>Continue until there is symptomatic and radiographic improvement</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="3"><em>Mycobacterium kansasii</em> infection</td> </tr> <tr> <td class="indent1">Rifampin-susceptible</td> <td> <ul> <li>Rifampin (rifampicin), <strong>plus</strong></li> <li>Ethambutol, <strong>plus</strong></li> <li>Either a macrolide (azithromycin [preferred*] or clarithromycin) <strong>or</strong> isoniazid<sup>◊</sup></li> </ul> </td> <td> <ul> <li>Continue until sputum cultures negative for ≥1 year</li> </ul> </td> </tr> <tr> <td class="indent1">Rifampin-resistant or intolerance to a first-line medication</td> <td> <ul> <li>Treat with 3 drugs based upon in vitro susceptibilities</li> <li>Options include macrolides, fluoroquinolones, aminoglycosides, and trimethoprim-sulfamethoxazole</li> </ul> </td> <td> <ul> <li>Continue until sputum cultures negative for 12 to 18 months</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table is meant for use with UpToDate content on NTM pulmonary infections in children. Refer to UpToDate content for additional details.</div><div class="graphic_footnotes"><p>NTM: nontuberculous mycobacteria; MAC: <em>Mycobacterium avium</em> complex (<em>M. avium</em> and <em>Mycobacterium intracellulare</em>).</p>
<p>* Azithromycin is generally preferred to clarithromycin because of once daily dosing and fewer drug interactions.</p>
<p>¶ It is reasonable to exclude pyrazinamide if the 5-drug regimen is too difficult.</p>
<p>Δ Although the macrolide may be continued for its immunomodulatory effects, it should not count as 1 of the active drugs.</p>
    
    ◊ Daily therapy is necessary for cavitary <em>M. kansasii</em> pulmonary disease or if isoniazid is included in the initial regimen. If a macrolide is included in the initial regimen for noncavitary <em>M. kansasii</em> pulmonary disease, therapy can be given 3 times per week.</div><div class="graphic_reference">References:
    <ol>
<li>Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.</li>
<li>American Academy of Pediatrics. Nontuberculous mycobacteria (environmental mycobacteria, mycobacteria other than Mycobacterium tuberculosis). In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32<sup>nd</sup> ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.814.</li>
<li>Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: An official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis 2020; 71:905.</li>
</ol></div><div id="graphicVersion">Graphic 131834 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
